Akorn, Inc. stock performance trend indicates that the stock price has rallied 2.81% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -18.12% . Looking at the past 52 week period, the stock price is up at 18.41% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Akorn, Inc. has a negative value of -24.95 compared to overall market performance.Akorn, Inc. is having a Relative Strength Index of 51.93 which indicates the stock is not yet over sold or over bought based on the technical indicators.
Akorn, Inc. (NASDAQ:AKRX) has tumbled 1.5% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 2.48% in the last four weeks. The stocks have underperformed the S&P 500 by 1.73% during the past week but Akorn, Inc. (NASDAQ:AKRX) it has outperformed the index in 4 weeks by 1.31%.
For the current week, the company shares have a recommendation consensus of Buy. Akorn, Inc. (NASDAQ:AKRX) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.5 points or 2.19% at $22.32 with 1,518,318 shares getting traded. Post opening the session at $22.96, the shares hit an intraday low of $22.27 and an intraday high of $22.96 and the price was in this range throughout the day. The company has a market cap of $2,777 million and the number of outstanding shares has been calculated to be 124,415,759 shares. The 52-week high of Akorn, Inc. (NASDAQ:AKRX) is $35.4 and the 52-week low is $17.57.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by WallachBeth on Mar 10, 2017 to Hold, Raises Price Target to $ 25 from a previous price target of $22 .
Company has reported several Insider transactions to the SEC, on Aug 16, 2016, Kenneth Abramowitz (director) sold 2,691 shares at 30.46 per share price.On Jun 14, 2016, Joseph Bonaccorsi (Sr VP Gen Counsel & Secretary) sold 6,500 shares at 29.84 per share price.On Jun 9, 2016, Ronald M Johnson (director) sold 7,542 shares at 31.49 per share price.
Akorn Last issued its quarterly earnings results on Mar 1, 2017. The company reported $0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $0.57. The company had revenue of $283.70 million for the quarter, compared to analysts expectations of $287.91 million. The companys revenue was up 1.3% compared to the same quarter last year.
Akorn, Inc. manufactures and markets diagnostic and therapeutic pharmaceuticals in specialty areas such as ophthalmology, rheumatology, anesthesia and antidotes, among others. They also market ophthalmic surgical instruments and related products. Customers include physicians, optometrists, wholesalers, group purchasing organizations and other pharmaceutical companies. They also provide contract manufacturing services.